The Medical Advisor

You’ve likely seen the claims: “Sugar feeds cancer — eliminate carbs.” “Keto starves tumors.” “Plant-based diets reverse cancer.” “Fasting kills cancer cells.” These ideas sound intuitive. Some are supported by laboratory or animal studies. Yet when tested rigorously in humans, most anti-cancer diet claims fail to show meaningful clinical benefit . This article explains why, what diet can realistically do for cancer risk and outcomes, and how nutrition fits into a modern, evidence-informed cancer strategy. 1. Lab Success Doesn’t Translate to Human Reality Many diet-based cancer claims originate from: Cell culture experiments Mouse models Short-term metabolic interventions In these controlled environments, researchers can deprive cancer cells of glucose or nutrients abruptly. Humans, however, are complex systems with: Multiple organs and hormones Immune responses Gut microbiomes Tumors that evolve and adapt What slows cancer growth in a dish often has minimal impact in real patients. R...

Abstract In 2022, approximately 20 million new cancer cases and 9.7 million cancer deaths occurred worldwide. By 2050, new cases are projected to double, driven by population growth, aging, and increased exposure to risk factors. Up to 40% of cancers may be preventable by addressing lifestyle and environmental risk factors. Numerous nutraceuticals and repurposed drugs exhibit chemoprophylactic properties. Epigallocatechin gallate (EGCG), a polyphenol in green tea, appears to be the most effective agent against multiple cancers, followed by curcumin, a . polyphenol derived from turmeric (Curcuma longa), vitamin D, and omega-3 fatty acids. Using artificial intelligence and leveraging synergistic effects among these compounds, we developed the ROOT 3, ROOT 4, ROOT 5, ROOT 6, and ROOT 9 chemoprophylactic protocols. The mechanistic activity of each nutraceutical is described, along with the estimated risk reduction for the most common types of cancer. These protocols may offer a low-risk an...

Insights from Dr. Paul Marik and Dr. Justus Hope on the hidden drivers of cancer relapse, featuring the revamped CSC Cancer Tree and practical strategies using repurposed drugs and natural compounds. Cancer treatment often succeeds—until it doesn’t. A tumor shrinks. A scan looks clean. The patient goes home hopeful. And then… the cancer returns, sometimes more aggressive than before. The answer lies with a small population of cells that most standard treatments ignore: cancer stem cells (CSCs). These cells not only survive chemotherapy and radiation but adapt and return, driving relapse, metastasis, and mortality.   Dr. Paul Marik and Dr. Justus Hope have collaborated to highlight this critical issue, offering a free guide that explains CSCs, why conventional therapies fail against them, and how safe, affordable repurposed drugs and natural compounds can target them for long-term remission. This guide builds on earlier work, including the CSC Cancer Tree from Dr. Hope's 2020 book,...